Low-dose Atropine for Myopia Control in Children
Key facts
- Who runs it
- University Eye Hospital, Freiburg
- Where
- Germany16 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2/3
- People taking part
- 302 people enrolled
- Started
- 19 Oct 2021
- Expected to end
- Nov 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- Atropine eye drops, 0.01%
- Atropine eye drops, 0.02%
- Placebo (NaCl 0.9%) eye drops
- Record updated
- 6 March 2025
Who can take part
- Age
- 8 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Male or female patients aged 8 to 12 years (up to the day before the 13th birthday)
- Myopia of -1 D to -6 D with reported or documented annual progression ≥ 0.5 D of myopia
- Written informed consent obtained from patient (if applicable) and parents or legal guardians according to international guidelines and local laws
- Ability to understand the nature of the trial and the trial related procedures and to comply with them
Who cannot take part
- Previous use of any kind of contact lenses
- Previous use of atropine eye drops
- Participation in any other interventional clinical trial within the last 30 days before the start of this trial
- History of amblyopia
- Any acquired or developmental organic eye disease
- Any known systemic metabolic disease or chromosomal anomaly
- Epilepsy
- Known hypersensitivity to the active substances or any of the excipients
- Caution and pediatric counselling shall be assured if any of the following conditions are present according to the Summary of Product Characteristics (SmPC): Cardiac insufficiency, arrhythmia, coronary stenosis, hyperthyroidism, stomach or bowel stenosis, bowel paralysis, megacolon, muscle weakness, lung edema, hypersensitivity to atropine, spastic paralysis
- Asian or African origin
- Abnormal binocularity
- Strabismus
- Astigmatism >1.5 D
- Anisometropia >1.5 D
- Corrected visual acuity in any eye <0.63
- Premature birth
- Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registries and diagnostic trials is allowed
- Contraindications according to the Summary of Product Characteristics (SmPC): Increased intraocular pressure (primary forms of glaucoma or narrow angle glaucoma), chronic rhinitis sicca
- Parents or children with poor understanding of the German language
- Person who is in a relationship of dependence/employment with the sponsor or the investigator
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Myopia (nearsightedness) is the most common eye disorder. Only second to age, it is the main risk factor for major degenerative eye diseases such as glaucoma, macular degeneration or retinal detachment. Their risk increases with the degree of myopia. Hence, prevention of myopia and slowing its progression is of high relevance. Almost all clinical studies, including two large randomised clinical trials (RCT) were performed in Asia with Asian study participants. The results indicate that atropine eye drops can attenuate myopic progression in children, even in low concentrations thus minimizing unwanted side effects. However, the cumulative evidence is yet not strong enough to recommend their unrestricted use, especially in a Non-Asian population. We therefore intend to set up an adequately powered RCT comparing atropine 0.02% eye drops with placebo to validate previous findings and to test whether this therapeutic concept holds its promise in a European population.
The 2 groups in the trial
- Arm A, Interventional groupTreatment being tested
Treatment period 1: Atropine eye drops, 0.02%, 1 drop/eye, daily for 12 months Treatment period 2: Atropine eye drops, 0.02%, 1 drop/eye, daily for 12 months Treatment period 3: Placebo (NaCl 0.9%) eye drops, 1 drop/eye, daily for 12 months
Treatment: Atropine eye drops, 0.02% and Placebo (NaCl 0.9%) eye drops
- Arm B, Control groupTreatment being tested
Treatment period 1: Placebo (NaCl 0.9%) eye drops, 1 drop/eye, daily for 12 months Treatment period 2: Atropine eye drops, 0.01%, 1 drop/eye, daily for 12 months Treatment period 3: Atropine eye drops, 0.01%, 1 drop/eye, daily for 12 months
Treatment: Atropine eye drops, 0.01% and Placebo (NaCl 0.9%) eye drops
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Low-dose Atropine for Myopia Control in Children, a Prospective, Double-blind, Placebo-controlled, Multicentric, Randomized Clinical Trial
- Publications
- Record updated
- 6 March 2025